Genovate Biotechnology Co., Ltd. Stock

Equities

4130

TW0004130000

Pharmaceuticals

End-of-day quote Taipei Exchange 18:00:00 2024-04-28 EDT 5-day change 1st Jan Change
24.35 TWD +1.25% Intraday chart for Genovate Biotechnology Co., Ltd. +2.31% -8.46%

Financials

Sales 2022 439M 13.49M 18.39M Sales 2023 529M 16.24M 22.15M Capitalization 2.91B 89.42M 122M
Net income 2022 -12M -369K -503K Net income 2023 29M 891K 1.22M EV / Sales 2022 6.86 x
Net cash position 2022 495M 15.22M 20.75M Net cash position 2023 539M 16.56M 22.57M EV / Sales 2023 4.49 x
P/E ratio 2022
-285 x
P/E ratio 2023
99.2 x
Employees 199
Yield 2022
0.54%
Yield 2023
0.56%
Free-Float 69.6%
More Fundamentals * Assessed data
Dynamic Chart
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Genovate Biotechnology Co., Ltd. Announces Members of the Company's 5th Remuneration Committee CI
Genovate Biotechnology Co., Ltd. Announces Cash Dividend, Payable August 7, 2023 CI
Genovate Biotechnology Co., Ltd. Approves Election of Directors CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Genovate Biotechnology Co., Ltd. and CSPC Pharmaceutical Group Limited Sign the Agreement on Technology Licensing and Co-Development of DBPR108 in Mainland China CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Audit Committee Member and Convener of the Remuneration Committee, Effective April 10, 2023 CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Independent Director, Effective April 10, 2023 CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day+1.25%
1 week+2.31%
Current month-2.60%
1 month-2.79%
3 months-4.32%
6 months-8.29%
Current year-8.46%
More quotes
1 week
24.00
Extreme 24
24.50
1 month
23.60
Extreme 23.6
25.40
Current year
23.60
Extreme 23.6
27.00
1 year
23.60
Extreme 23.6
31.95
3 years
20.85
Extreme 20.85
41.85
5 years
16.15
Extreme 16.1476
51.42
10 years
16.15
Extreme 16.1476
72.87
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-06-22
Director of Finance/CFO - 09-03-31
Chairman 69 93-02-13
Members of the board TitleAgeSince
Chairman 69 93-02-13
Director/Board Member 62 14-06-09
Director/Board Member 58 17-05-31
More insiders
Date Price Change Volume
24-04-28 24.35 +1.25% 243 086
24-04-26 24.05 -0.21% 152,244
24-04-25 24.1 -0.82% 129,821
24-04-24 24.3 +0.21% 208,627
24-04-23 24.25 +1.46% 202,714

End-of-day quote Taipei Exchange, April 28, 2024

More quotes
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
More about the company